Department of Bioinformatics and Biotechnology, International Islamic University, Islamabad, Pakistan.
Department of Cardiology, PAF Hospital, Islamabad, E-9, Pakistan.
Biol Trace Elem Res. 2023 Nov;201(11):5213-5229. doi: 10.1007/s12011-023-03579-2. Epub 2023 Jan 25.
Polycystic ovarian syndrome (PCOS) is considered the most frequent gynecological endocrine disorder that causes anovulatory infertility. The current study aimed to investigate the potential significance of selenium nanoparticles (SeNPs), an IL-1 inhibitor, in the treatment of letrozole-induced PCOS in rats that satisfied the metabolic and endocrine parameters found in PCOS patients. Letrozole (2 ppm, per orally, p.o.) was given orally to female Wistar rats for 21 days to develop PCOS. After PCOS induction, rats were given SeNPs (25 ppm/day, p.o.), SeNPs (50 ppm/day, p.o.), or metformin (2 ppm/day, p.o.) for 14 days. PCOS was associated with an increase in body weight, ovarian weight, ovarian size, and cysts, as well as an increase in blood testosterone, luteinizing hormone (LH), and insulin, glycaemia, and lipid profile levels. The SeNP administration decreased all of these variables. Furthermore, SeNPs significantly reduced letrozole-induced oxidative stress in the ovaries, muscles, and liver by decreasing elevated levels of malondialdehyde and total nitrite while raising suppressed levels of superoxide dismutase and catalase. SeNPs increased the amounts of the protective proteins Kelch-like ECH-associated protein 1 (Keap-1), nuclear factor erythroid 2-related factor 2 (Nrf2), and OH-1. It was depicted from the study that SeNPs reduce the upregulation of inflammatory cytokines that are interleukin 6 (IL-6), tumour necrosis factor α (TNF-α), and the interleukin 1 (IL-1). Our findings show that SeNPs, through their antioxidant and anti-inflammatory characteristics, alleviate letrozole-induced PCOS.
多囊卵巢综合征（PCOS）被认为是最常见的妇科内分泌紊乱疾病，可导致排卵障碍性不孕。本研究旨在探讨硒纳米粒子（SeNPs）作为一种白介素 1 抑制剂，在治疗符合 PCOS 患者代谢和内分泌参数的来曲唑诱导的 PCOS 大鼠中的潜在意义。用 2ppm（口服，p.o.）来曲唑连续 21 天给雌性 Wistar 大鼠口服以诱导 PCOS。诱导 PCOS 后，大鼠连续 14 天给予 SeNPs（25ppm/d，p.o.）、SeNPs（50ppm/d，p.o.）或二甲双胍（2ppm/d，p.o.）。PCOS 导致体重、卵巢重量、卵巢大小和囊肿增加，以及血液睾酮、黄体生成素（LH）和胰岛素、血糖和血脂水平升高。SeNP 给药降低了所有这些变量。此外，SeNPs 通过降低丙二醛和总亚硝酸盐的升高水平，同时提高超氧化物歧化酶和过氧化氢酶的抑制水平，显著降低了来曲唑诱导的卵巢、肌肉和肝脏中的氧化应激。SeNPs 增加了保护性蛋白 Kelch 样 ECH 相关蛋白 1（Keap-1）、核因子红细胞 2 相关因子 2（Nrf2）和 OH-1 的含量。研究表明，SeNPs 降低了白介素 6（IL-6）、肿瘤坏死因子 α（TNF-α）和白介素 1（IL-1）等炎症细胞因子的上调。我们的研究结果表明，SeNPs 通过其抗氧化和抗炎特性缓解来曲唑诱导的 PCOS。
